ArticleBMC infectious diseases2025
Global burden of HIV and drug-resistant tuberculosis co-infection and its attributable risk factors, 1990 to 2021, with projections to 2031.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Current and emerging therapies for pulmonary tuberculosis in adults.BMJ medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe persistent global spread of HIV and drug-resistant tuberculosis (HIV/DR-TB) co-infection poses a significant challenge to international tuberculosis control efforts. This study aimed to analyze the global burden of HIV/DR-TB co-infection across age groups, genders, and Socio-demographic Index (SDI) regions, while identifying attributable risk factors.
methodsData from the Global Burden of Disease (GBD) 2021 and joinpoint regression analysis were utilized to examine epidemiological trends from 1990 to 2021 across different genders and SDI regions. The Bayesian Age-Period-Cohort (BAPC) model was employed to forecast trends up to 2031.
resultsHIV and multidrug-resistant tuberculosis (HIV/MDR-TB) co-infection exhibited no significant gender differences in prevalence, incidence, mortality, or DALYs (P = 0.053, 0.277, 0.354, 0.212). In contrast, HIV and extensively drug-resistant tuberculosis (HIV/XDR-TB) co-infection showed significantly higher rates in males for all outcomes (P = 0.007, 0.003, 0.003, 0.005). Burden distribution varied by SDI quintile: Low SDI bore a greater HIV/MDR-TB co-infection burden. High-middle SDI had higher HIV/XDR-TB co-infection prevalence. Unsafe sex was the predominant risk factor for HIV/DR-TB co-infections in both genders, followed by drug use in males and intimate partner violence in females. Regional risk patterns revealed that male drug use was more strongly associated with HIV/DR-TB co-infection in high-middle SDI regions, whereas unsafe sex and intimate partner violence (in females) showed greater impact in low SDI regions. Projections indicated a steady decline in HIV/DR-TB co-infection from 2021 to 2031.
conclusionDespite observed declines, HIV/DR-TB co-infection continues to pose a significant public health challenge. Regional SDI-stratified interventions are urgently needed: low-SDI settings should prioritize healthcare system strengthening to address gender-specific vulnerabilities including unsafe sexual practices and intimate partner violence, while high-middle SDI regions require comprehensive drug abuse prevention programs combining public education with enhanced pharmaceutical controls.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.